Profound Medical Corp (PROF) Stock AnalysisPROFStock AnalysisProfound Medical Corp

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Profound Medical Corp is currently priced at $6.85, which is below the analyst price target of $11, indicating potential upside. However, the stock has a low RSI of 45.208, suggesting it is neither overbought nor oversold, and recent earnings showed a revenue miss at $2.48 million against an estimate of $5.58 million, raising concerns about future growth. The main risk is the company’s negative earnings trend, with a reported EPS of -0.26, which could affect investor sentiment.